HomeCompareLPTX vs EPRT

LPTX vs EPRT: Dividend Comparison 2026

LPTX yields 304.60% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LPTX wins by $1677.43M in total portfolio value
10 years
LPTX
LPTX
● Live price
304.60%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1677.50M
Annual income
$1,019,249,502.55
Full LPTX calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — LPTX vs EPRT

📍 LPTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLPTXEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LPTX + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LPTX pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LPTX
Annual income on $10K today (after 15% tax)
$25,890.95/yr
After 10yr DRIP, annual income (after tax)
$866,362,077.17/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, LPTX beats the other by $866,351,162.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LPTX + EPRT for your $10,000?

LPTX: 50%EPRT: 50%
100% EPRT50/50100% LPTX
Portfolio after 10yr
$838.78M
Annual income
$509,631,171.64/yr
Blended yield
60.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

LPTX
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Price Target
$5.50
+737.6% upside vs current
Range: $5.50 — $5.50
Altman Z
-1.9
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LPTX buys
0
EPRT buys
0
No recent congressional trades found for LPTX or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLPTXEPRT
Forward yield304.60%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$1677.50M$63.4K
Annual income after 10y$1,019,249,502.55$12,840.73
Total dividends collected$1611.81M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$5.50$35.50

Year-by-year: LPTX vs EPRT ($10,000, DRIP)

YearLPTX PortfolioLPTX Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$41,160$30,459.95$11,205$505.18+$30.0KLPTX
2$161,212$117,171.00$12,672$682.46+$148.5KLPTX
3$601,400$428,903.22$14,490$930.48+$586.9KLPTX
4$2,138,843$1,495,344.84$16,786$1,282.69+$2.12MLPTX
5$7,258,751$4,970,189.23$19,753$1,791.56+$7.24MLPTX
6$23,531,071$15,764,207.60$23,677$2,541.64+$23.51MLPTX
7$72,938,668$47,760,421.89$29,008$3,672.99+$72.91MLPTX
8$216,401,174$138,356,798.39$36,463$5,425.08+$216.36MLPTX
9$615,184,508$383,635,252.06$47,238$8,221.57+$615.14MLPTX
10$1,677,496,926$1,019,249,502.55$63,385$12,840.73+$1677.43MLPTX

LPTX vs EPRT: Complete Analysis 2026

LPTXStock

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Full LPTX Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this LPTX vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LPTX vs SCHDLPTX vs JEPILPTX vs OLPTX vs KOLPTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.